Daniel L. Flynn
2020
In 2020, Daniel L. Flynn earned a total compensation of $2.7M as EVP, Founder and Chief Scientific Officer at Deciphera Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $269,112 |
|---|---|
| Option Awards | $1,546,335 |
| Salary | $442,000 |
| Stock Awards | $386,285 |
| Other | $11,400 |
| Total | $2,655,132 |
Flynn received $1.5M in option awards, accounting for 58% of the total pay in 2020.
Flynn also received $269.1K in non-equity incentive plan, $442K in salary, $386.3K in stock awards and $11.4K in other compensation.
Rankings
In 2020, Daniel L. Flynn's compensation ranked 4,322nd out of 13,090 executives tracked by ExecPay. In other words, Flynn earned more than 67.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,322 out of 13,090 | 67th |
Division Manufacturing | 1,753 out of 5,621 | 69th |
Major group Chemicals And Allied Products | 685 out of 2,254 | 70th |
Industry group Drugs | 586 out of 1,954 | 70th |
Industry Pharmaceutical Preparations | 446 out of 1,459 | 69th |
Source: SEC filing on April 26, 2022.
Flynn's colleagues
We found four more compensation records of executives who worked with Daniel L. Flynn at Deciphera Pharmaceuticals in 2020.